Recommendation of the President – Fasenra (benralizumab)

On 12 March 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No.29/2025 on the appraisal of Fasenra (benralizumab) as part of the drug program “Treatment of patients with systemic vasculitis (ICD-10: M31.3, M31.5, M31.6, M31.7, M31.8)”

Publication in Public Information Bulletin (BIP) >>